Population-wide screening for stomach bacteria could fundamentally shift cancer prevention strategies, moving beyond symptomatic treatment to proactive elimination of a major carcinogenic threat. The International Agency for Research on Cancer has evaluated evidence supporting systematic Helicobacter pylori detection and eradication programs as a primary prevention tool against gastric malignancy. The IARC Working Group's comprehensive assessment examined real-world screening implementations across diverse populations, analyzing both effectiveness metrics and implementation challenges. Their findings indicate that organized screen-and-treat initiatives can meaningfully reduce gastric cancer incidence when applied at population scale, particularly in regions with elevated baseline risk. The bacterial pathogen, present in roughly half of all adults globally, triggers chronic inflammation that can progress to precancerous changes and eventually adenocarcinoma over decades. This represents a paradigm evolution in cancer prevention methodology, treating an infectious agent before malignant transformation occurs rather than detecting early-stage tumors. However, the Working Group's analysis likely addresses critical implementation considerations including antibiotic resistance concerns, healthcare infrastructure requirements, and cost-effectiveness across different demographic contexts. The gastric cancer burden varies dramatically by geography, with East Asian populations experiencing rates ten times higher than Western countries, suggesting targeted screening may prove more viable than universal approaches. While H. pylori eradication therapy achieves cure rates exceeding 90% with appropriate antibiotic combinations, the optimal screening intervals, target populations, and integration with existing healthcare systems remain active areas of investigation requiring careful regional adaptation.